# Immix Biopharma (IMMX) — News

IMMX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/immx/news

## Recent headlines

- [Immix Biopharma, Inc.: Immix Biopharma: Closing of $125M underwritten offering of stock](https://www.ainvest.com/news/immix-biopharma-immix-biopharma-closing-125m-underwritten-offering-stock-2610) — AInvest Wire, Sep 30, 2026
  Immix Biopharma, Inc. (NASDAQ: IMMX) has completed a $125 million underwritten public offering of its common stock, according to recent disclosures. The offering, which was oversubscribed, reflects strong investor interest in the company’s pipeline of therapies targeting rare diseases and oncology…
- [Immix Biopharma prices offer of 11.36M sharees at $11 each](https://www.ainvest.com/news/immix-biopharma-prices-offer-11-36m-sharees-11-2609) — AInvest Wire, Sep 29, 2026
  Immix Biopharma has announced the pricing of its recent share offering, which includes 11.36 million shares priced at $11 per share. The offering is part of the company’s ongoing efforts to raise capital for research and development initiatives. No further details regarding the use of proceeds or…
- [IMMIXBio's NXC-201 posts 89% CR rate in Nextricart-2](https://www.ainvest.com/news/immixbio-nxc-201-posts-89-cr-rate-nextricart-2-2609) — AInvest Wire, Sep 29, 2026
  Immix Biopharma, Inc. (IMMX) recently reported an 89% complete response rate for its investigational therapy NXC-201 in the NEXICART-2 clinical trial as of September 2026. The trial, a Phase 2, multi-site U.S. study (NCT06097832), is evaluating the sterically-optimized CAR-T therapy in patients…
- [IMMIX Biopharma, - Net proceeds to fund NXC-201 development, working capital, corporate purposes](https://www.ainvest.com/news/immix-biopharma-net-proceeds-fund-nxc-201-development-working-capital-corporate-purposes-2609) — AInvest Wire, Sep 29, 2026
- [IMMIX Biopharma, - Prices 11,363,637 shares at $11 per share](https://www.ainvest.com/news/immix-biopharma-prices-11-363-637-shares-11-share-2609) — AInvest Wire, Sep 29, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).